Adding drug to presurgery chemotherapy improves results for women with...
The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the...
View ArticleFNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for...
The I-SPY 2 TRIAL, a randomized phase II clinical trial for breast cancer launched through a unique partnership with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium...
View ArticleAbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013
AbbVie today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.
View ArticleSynta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY...
Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL...
View ArticleOral cancer drug improves outcomes in women with resistant gynecologic cancers
An oral cancer drug improves outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies, suggests...
View ArticleCedars-Sinai investigators developing novel treatment for locally advanced...
Investigators at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute are developing a novel, multistep investigational treatment for one of the most complex and difficult-to-treat forms of...
View ArticleAbbvie announces multiple study results of veliparib investigational compound...
AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in...
View ArticleAbbVie and Myriad Genetics expand Tumor BRACAnalysis CDx collaboration
Myriad Genetics, Inc. announced today that it has signed an expanded companion diagnostic agreement with AbbVie, Inc., a leading global biopharmaceutical company to use Tumor BRACAnalysis CDx™ as a...
View ArticlePhase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015
AbbVie, a global biopharmaceutical company, today announced findings from a Phase 2 study of the investigational medicine veliparib combined with the chemotherapy regimen carboplatin and paclitaxel...
View ArticleCertain ARID1a mutations sensitize some tumors to PARP inhibitor drugs
Mutations in ARID1a, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress. This gene may also be an Achilles' heel when treating certain...
View ArticleI-SPY2 research initiative employs exciting new model for testing breast...
In a new paradigm of breast cancer research, physicians are fast-tracking promising new experimental drugs for further study, while immediately dropping drugs and drug combinations that don't work.
View ArticleFNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for...
The I-SPY 2 TRIAL, a randomized phase II clinical trial for breast cancer launched through a unique partnership with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium...
View ArticleAbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013
AbbVie today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.
View ArticleSynta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY...
Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL...
View ArticleOral cancer drug improves outcomes in women with resistant gynecologic cancers
An oral cancer drug improves outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies, suggests...
View ArticleCedars-Sinai investigators developing novel treatment for locally advanced...
Investigators at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute are developing a novel, multistep investigational treatment for one of the most complex and difficult-to-treat forms of...
View ArticleAbbvie announces multiple study results of veliparib investigational compound...
AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in...
View ArticleAbbVie and Myriad Genetics expand Tumor BRACAnalysis CDx collaboration
Myriad Genetics, Inc. announced today that it has signed an expanded companion diagnostic agreement with AbbVie, Inc., a leading global biopharmaceutical company to use Tumor BRACAnalysis CDx™ as a...
View ArticlePhase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015
AbbVie, a global biopharmaceutical company, today announced findings from a Phase 2 study of the investigational medicine veliparib combined with the chemotherapy regimen carboplatin and paclitaxel...
View ArticleCertain ARID1a mutations sensitize some tumors to PARP inhibitor drugs
Mutations in ARID1a, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress. This gene may also be an Achilles' heel when treating certain...
View Article
